JLE

Innovations & Thérapeutiques en Oncologie

MENU

The clinical use of anti-CTLA-4 antibodies Volume 3, issue 3-4, May-August 2017

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4
Authors
Hôpital de la Timone, Pavillon E-F
Dermatologie, vénéréologie et cancérologie cutanée
264, rue Saint-Pierre
13385 Marseille Cedex 5
France
* Tirés à part

The use of anti-CTLA-4 monoclonal antibody against metastatic melanoma has provided the first clinical proof that targeting immune checkpoints could be of therapeutic value in cancerology. The concept is based on the fact that monoclonal antibodies block the activity of inhibitory coreceptors expressed on the surface of T-lymphocytes infiltrating tumours. This blocking stimulates the immune responses to act against the tumour cells. This article describes the use of anti-CTLA-4 antibodies in treatment, including initial successes, which have encouraged research in immunotherapy, and limitations resulting from its low response rate.